Grabowski G A, Dagan A
Anal Biochem. 1984 Aug 15;141(1):267-79. doi: 10.1016/0003-2697(84)90456-1.
Two Sepharose-bound substrate analogs, 6'-aminohexanoyl-(2-N-sphingosyl-O-beta-D-glucoside) and 6'-aminohexyl-dodecanedioyl-1-(2-N-sphingosyl-1-O-beta-D-glu coside), were synthesized and used sequentially for the affinity purification of lysosomal beta-glucosidase (N-acyl-sphingosyl-1-O-beta-D-glucoside:glucohydrolase, EC 3.2.1.45). The capacities of these nondegradable affinity supports were 0.1 and 0.15 mg enzyme/ml settled gel, respectively. The purified enzyme had a specific activity of 75 mumol min-1 mg-1. The preparation had a single protein band with a molecular weight of 67,000 on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, evidencing its apparent homogeneity. Isoelectric focusing on granular gels revealed four molecular forms of the enzyme with pI values of 4.0, 4.5, 4.7, and 5.8 to 6.2. The purified enzyme hydrolyzed glucosyl ceramide and 4-methylumbelliferyl-beta-D-glucoside with Km and Vmax values of 0.6 and 2.5 mM, and 101 and 26.1 mumol min-1 mg-1, respectively. The enzyme also hydrolyzed octyl beta-glucoside, a linear mixed-type inhibitor of the enzyme. Binding constants (Ki) were determined for the inhibitors, sphingosyl-1-O-beta-D-glucoside (Ki = 20 microM) and its N-hexyl derivative (Ki = 0.3 microM). The enzyme had a half-life of 65 and 30 min at 50 degrees C and pH 5.0 or 6.0, respectively. In addition, two other classes of ligands were used for the purification of lysosomal beta-glucosidase, and their capacities and specificities were compared to those of the substrate analog affinity supports. These included (i) the alkyl amine inhibitors octylamine, decylamine, and tetradecylamine; and (ii) the inhibitors, 6-aminohexanoyl-beta-glucosylamine and aminododecanoyl-1-(2-N-sphingosyl-1-O-beta-D-glucoside). Compared to these other ligand columns, the substrate analog affinity supports had about 100- to 1000-fold greater capacities or afforded 8- to 40-fold greater purification of human lysosomal beta-glucosidase.
合成了两种与琼脂糖结合的底物类似物,即6'-氨基己酰基-(2-N-鞘氨醇基-O-β-D-葡萄糖苷)和6'-氨基己基-十二烷二酰基-1-(2-N-鞘氨醇基-1-O-β-D-葡萄糖苷),并依次用于溶酶体β-葡萄糖苷酶(N-酰基-鞘氨醇基-1-O-β-D-葡萄糖苷:葡萄糖水解酶,EC 3.2.1.45)的亲和纯化。这些不可降解的亲和支持物的容量分别为0.1和0.15 mg酶/ml沉降凝胶。纯化后的酶比活性为75 μmol min⁻¹ mg⁻¹。该制剂在十二烷基硫酸钠-聚丙烯酰胺凝胶电泳上有一条分子量为67,000的单一蛋白带,表明其明显均一。在颗粒凝胶上进行等电聚焦显示该酶有四种分子形式,其pI值分别为4.0、4.5、4.7和5.8至6.2。纯化后的酶水解葡糖神经酰胺和4-甲基伞形酮基-β-D-葡萄糖苷,其Km和Vmax值分别为0.6和2.5 mM,以及101和26.1 μmol min⁻¹ mg⁻¹。该酶还水解辛基β-葡萄糖苷,它是该酶的一种线性混合型抑制剂。测定了抑制剂鞘氨醇基-1-O-β-D-葡萄糖苷(Ki = 20 μM)及其N-己基衍生物(Ki = 0.3 μM)的结合常数(Ki)。该酶在50℃和pH 5.0或6.0时的半衰期分别为65和30分钟。此外,还使用了另外两类配体用于溶酶体β-葡萄糖苷酶的纯化,并将它们的容量和特异性与底物类似物亲和支持物的进行了比较。这些配体包括:(i)烷基胺抑制剂辛胺、癸胺和十四胺;以及(ii)抑制剂6-氨基己酰基-β-葡萄糖胺和氨基十二烷酰基-1-(2-N-鞘氨醇基-1-O-β-D-葡萄糖苷)。与这些其他配体柱相比,底物类似物亲和支持物的容量大100至1000倍,或者对人溶酶体β-葡萄糖苷酶的纯化效果提高8至40倍。